Fexofenadine reduces nasal congestion in perennial allergic rhinitis

G. Ciprandi, C. Cosentino, M. Milanese, C. Mondino, G. W. Canonica

Research output: Contribution to journalArticle

Abstract

Background: Nasal congestion is the predominant symptom in perennial allergic rhinitis (PAR), and it seems to be mainly related to the late-phase inflammatory events. The present pilot study aimed to evaluate the therapeutic effect exerted by fexofenadine in patients with PAR due to mite allergy. Methods: This study was a parallel, double-blind, randomized, three-arm (1:1:1), placebo-controlled study. Thirty-one subjects with PAR were enrolled and received double-blind medication: fexofenadine 120 or 180 mg, or placebo, once a day for 28 days. Results: The total symptom score was reduced by fexofenadine (both dosages) at V2 (P = 0.007), whereas placebo did not modify it. Nasal congestion decreased after 1 week of treatment with fexofenadine 120 (P = 0.027) and 180 (P = 0.01), but not with placebo (P = NS). At V3, fexofenadine (both dosages) significantly reduced nasal congestion (P = 0.011 and P = 0.007, respectively), by placebo did not show any significant effect. Conclusions: This pilot study represents the first evidence of the efficacy of fexofenadine in PAR, and also the control of the nasal congestion. We suggest performing larger trials to confirm these preliminary findings.

Original languageEnglish
Pages (from-to)1068-1070
Number of pages3
JournalAllergy: European Journal of Allergy and Clinical Immunology
Volume56
Issue number11
DOIs
Publication statusPublished - 2001

Fingerprint

fexofenadine
Rhinitis, Allergic, Perennial
Nose
Placebos
Mites
Therapeutic Uses
Hypersensitivity

Keywords

  • Fexofenadine
  • Perennial allergic rhinitis

ASJC Scopus subject areas

  • Immunology

Cite this

Fexofenadine reduces nasal congestion in perennial allergic rhinitis. / Ciprandi, G.; Cosentino, C.; Milanese, M.; Mondino, C.; Canonica, G. W.

In: Allergy: European Journal of Allergy and Clinical Immunology, Vol. 56, No. 11, 2001, p. 1068-1070.

Research output: Contribution to journalArticle

Ciprandi, G. ; Cosentino, C. ; Milanese, M. ; Mondino, C. ; Canonica, G. W. / Fexofenadine reduces nasal congestion in perennial allergic rhinitis. In: Allergy: European Journal of Allergy and Clinical Immunology. 2001 ; Vol. 56, No. 11. pp. 1068-1070.
@article{3f7afab1d2c04734a0d6a311f4e2e834,
title = "Fexofenadine reduces nasal congestion in perennial allergic rhinitis",
abstract = "Background: Nasal congestion is the predominant symptom in perennial allergic rhinitis (PAR), and it seems to be mainly related to the late-phase inflammatory events. The present pilot study aimed to evaluate the therapeutic effect exerted by fexofenadine in patients with PAR due to mite allergy. Methods: This study was a parallel, double-blind, randomized, three-arm (1:1:1), placebo-controlled study. Thirty-one subjects with PAR were enrolled and received double-blind medication: fexofenadine 120 or 180 mg, or placebo, once a day for 28 days. Results: The total symptom score was reduced by fexofenadine (both dosages) at V2 (P = 0.007), whereas placebo did not modify it. Nasal congestion decreased after 1 week of treatment with fexofenadine 120 (P = 0.027) and 180 (P = 0.01), but not with placebo (P = NS). At V3, fexofenadine (both dosages) significantly reduced nasal congestion (P = 0.011 and P = 0.007, respectively), by placebo did not show any significant effect. Conclusions: This pilot study represents the first evidence of the efficacy of fexofenadine in PAR, and also the control of the nasal congestion. We suggest performing larger trials to confirm these preliminary findings.",
keywords = "Fexofenadine, Perennial allergic rhinitis",
author = "G. Ciprandi and C. Cosentino and M. Milanese and C. Mondino and Canonica, {G. W.}",
year = "2001",
doi = "10.1034/j.1398-9995.2001.00191.x",
language = "English",
volume = "56",
pages = "1068--1070",
journal = "Allergy: European Journal of Allergy and Clinical Immunology",
issn = "0105-4538",
publisher = "Wiley-Blackwell",
number = "11",

}

TY - JOUR

T1 - Fexofenadine reduces nasal congestion in perennial allergic rhinitis

AU - Ciprandi, G.

AU - Cosentino, C.

AU - Milanese, M.

AU - Mondino, C.

AU - Canonica, G. W.

PY - 2001

Y1 - 2001

N2 - Background: Nasal congestion is the predominant symptom in perennial allergic rhinitis (PAR), and it seems to be mainly related to the late-phase inflammatory events. The present pilot study aimed to evaluate the therapeutic effect exerted by fexofenadine in patients with PAR due to mite allergy. Methods: This study was a parallel, double-blind, randomized, three-arm (1:1:1), placebo-controlled study. Thirty-one subjects with PAR were enrolled and received double-blind medication: fexofenadine 120 or 180 mg, or placebo, once a day for 28 days. Results: The total symptom score was reduced by fexofenadine (both dosages) at V2 (P = 0.007), whereas placebo did not modify it. Nasal congestion decreased after 1 week of treatment with fexofenadine 120 (P = 0.027) and 180 (P = 0.01), but not with placebo (P = NS). At V3, fexofenadine (both dosages) significantly reduced nasal congestion (P = 0.011 and P = 0.007, respectively), by placebo did not show any significant effect. Conclusions: This pilot study represents the first evidence of the efficacy of fexofenadine in PAR, and also the control of the nasal congestion. We suggest performing larger trials to confirm these preliminary findings.

AB - Background: Nasal congestion is the predominant symptom in perennial allergic rhinitis (PAR), and it seems to be mainly related to the late-phase inflammatory events. The present pilot study aimed to evaluate the therapeutic effect exerted by fexofenadine in patients with PAR due to mite allergy. Methods: This study was a parallel, double-blind, randomized, three-arm (1:1:1), placebo-controlled study. Thirty-one subjects with PAR were enrolled and received double-blind medication: fexofenadine 120 or 180 mg, or placebo, once a day for 28 days. Results: The total symptom score was reduced by fexofenadine (both dosages) at V2 (P = 0.007), whereas placebo did not modify it. Nasal congestion decreased after 1 week of treatment with fexofenadine 120 (P = 0.027) and 180 (P = 0.01), but not with placebo (P = NS). At V3, fexofenadine (both dosages) significantly reduced nasal congestion (P = 0.011 and P = 0.007, respectively), by placebo did not show any significant effect. Conclusions: This pilot study represents the first evidence of the efficacy of fexofenadine in PAR, and also the control of the nasal congestion. We suggest performing larger trials to confirm these preliminary findings.

KW - Fexofenadine

KW - Perennial allergic rhinitis

UR - http://www.scopus.com/inward/record.url?scp=0034751569&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0034751569&partnerID=8YFLogxK

U2 - 10.1034/j.1398-9995.2001.00191.x

DO - 10.1034/j.1398-9995.2001.00191.x

M3 - Article

C2 - 11703220

AN - SCOPUS:0034751569

VL - 56

SP - 1068

EP - 1070

JO - Allergy: European Journal of Allergy and Clinical Immunology

JF - Allergy: European Journal of Allergy and Clinical Immunology

SN - 0105-4538

IS - 11

ER -